Soligenix, Inc. (SNGX) News
Filter SNGX News Items
SNGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNGX News Highlights
- For SNGX, its 30 day story count is now at 6.
- Over the past 24 days, the trend for SNGX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SNGX are RARE, CELL and DRUG.
Latest SNGX News From Around the Web
Below are the latest news stories about SOLIGENIX INC that investors may wish to consider to help them evaluate SNGX as an investment opportunity.
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)RedChip Companies will air new interviews with Soligenix, Inc. (Nasdaq:SNGX) and Graphex Group Limited (NYSE American:GRFX) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 3, at 7 p.m. Eastern Time (ET). |
SNGX: Positive Results for Compatibility Study of HyBryte in CTCLBy David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results from Compatibility Study of HyBryte™ in CTCL On May 4, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced positive results from a compatibility study of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The purpose of the |
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral MucositisSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted a patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis". This granted patent builds on similar intellectual property issued in the United States (U.S.), New Zealand, Japan, Australia and Singapore |
Soligenix Announces Recent Accomplishments And First Quarter 2023 Financial ResultsSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2023. |
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug Administration (FDA) has granted a Type A meeting to discuss the design of a second, Phase 3 pivotal study evaluating HyBryte™ (hypericin sodium) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, whe |
Soligenix Announces Closing of $8.5 Million Public OfferingSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and common warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30. The common warrants |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
Soligenix Announces Pricing of $8.5 Million Public OfferingSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 6,538,500 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,538,500 shares of common stock at a combined public offering price of $1.30 per share and accompanying warrant for aggregate |
Why Are Soligenix Shares Trading Higher TodaySoligenix Inc (NASDAQ: SNGX) released clinical results from a compatibility study evaluating HyBryte for cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. Daavlin device recently received 510(k) clearance from the FDA. HyBryte is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions taken up by the malignant T-cells and then activated by visible light approximately 24 hours later. The open-label study (protocol |
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a compatibility study evaluating HyBryte™ (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device, which recently received 510(k) clearance from U.S. |